An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.


Trump Bans CNN, MS NOW and Politico From White House
US, Japan and South Korea Back Taiwan Ahead of Trump-Xi Summit
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk
UK Home Asking Prices Rise for First Time Since May
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Yen Weakens as Dollar Gains on Widening US-Japan Rate Gap
Prysmian, Rio Tinto Supply Low-Carbon Cables for Amazon Ohio Data Center
White House Bars CNN, MS NOW and Politico Reporters
Nike Earnings at Risk as UBS Cuts Price Target to $42
Meta Partners With Shopify to Bring Shop Pay Checkout to Muse AI
Oil Prices Tumble on U.S.-Iran Diplomacy Hopes, Supply Relief
Wall Street Surges as Meta Leads AI Rally, Oil Prices Fall
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 



